KIDS Quote, Financials, Valuation and Earnings

Innovative Eyewear, Inc. has a net margin of -19.22% compared to OrthoPediatrics Corp.'s net margin of -274.85%. OrthoPediatrics Corp.'s return on equity of -12.83% beat Innovative Eyewear, Inc.'s return on equity of -80%.

OrthoPediatrics Corp. has a consensus price target of $24.14, signalling upside risk potential of 32.87%. On the other hand Innovative Eyewear, Inc. has an analysts' consensus of $3.00 which suggests that it could grow by 104.08%. Given that Innovative Eyewear, Inc. has higher upside potential than OrthoPediatrics Corp., analysts believe Innovative Eyewear, Inc. is more attractive than OrthoPediatrics Corp..

OrthoPediatrics Corp. has a beta of 1.062, which suggesting that the stock is 6.186% more volatile than S&P 500. In comparison Innovative Eyewear, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OrthoPediatrics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrthoPediatrics Corp. pays -- of its earnings as a dividend. Innovative Eyewear, Inc. pays out -- of its earnings as a dividend.

OrthoPediatrics Corp. quarterly revenues are $61.3M, which are larger than Innovative Eyewear, Inc. quarterly revenues of $668.1K. OrthoPediatrics Corp.'s net income of -$11.8M is lower than Innovative Eyewear, Inc.'s net income of -$1.8M. Notably, OrthoPediatrics Corp.'s price-to-earnings ratio is -- while Innovative Eyewear, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics Corp. is 1.87x versus 2.00x for Innovative Eyewear, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NexGel, Inc. has a net margin of -19.22% compared to OrthoPediatrics Corp.'s net margin of -22.05%. OrthoPediatrics Corp.'s return on equity of -12.83% beat NexGel, Inc.'s return on equity of -51.15%.

OrthoPediatrics Corp. has a consensus price target of $24.14, signalling upside risk potential of 32.87%. On the other hand NexGel, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 265.85%. Given that NexGel, Inc. has higher upside potential than OrthoPediatrics Corp., analysts believe NexGel, Inc. is more attractive than OrthoPediatrics Corp..

OrthoPediatrics Corp. has a beta of 1.062, which suggesting that the stock is 6.186% more volatile than S&P 500. In comparison NexGel, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OrthoPediatrics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrthoPediatrics Corp. pays -- of its earnings as a dividend. NexGel, Inc. pays out -- of its earnings as a dividend.

OrthoPediatrics Corp. quarterly revenues are $61.3M, which are larger than NexGel, Inc. quarterly revenues of $2.9M. OrthoPediatrics Corp.'s net income of -$11.8M is lower than NexGel, Inc.'s net income of -$647K. Notably, OrthoPediatrics Corp.'s price-to-earnings ratio is -- while NexGel, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics Corp. is 1.87x versus 1.07x for NexGel, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -19.22% compared to OrthoPediatrics Corp.'s net margin of 7.29%. OrthoPediatrics Corp.'s return on equity of -12.83% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

OrthoPediatrics Corp. has a consensus price target of $24.14, signalling upside risk potential of 32.87%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that OrthoPediatrics Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe OrthoPediatrics Corp. is more attractive than Phibro Animal Health Corp..

OrthoPediatrics Corp. has a beta of 1.062, which suggesting that the stock is 6.186% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

OrthoPediatrics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. OrthoPediatrics Corp. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

OrthoPediatrics Corp. quarterly revenues are $61.3M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. OrthoPediatrics Corp.'s net income of -$11.8M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, OrthoPediatrics Corp.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics Corp. is 1.87x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

STAAR Surgical Co. has a net margin of -19.22% compared to OrthoPediatrics Corp.'s net margin of 9.38%. OrthoPediatrics Corp.'s return on equity of -12.83% beat STAAR Surgical Co.'s return on equity of -25.83%.

OrthoPediatrics Corp. has a consensus price target of $24.14, signalling upside risk potential of 32.87%. On the other hand STAAR Surgical Co. has an analysts' consensus of $25.88 which suggests that it could fall by -2.73%. Given that OrthoPediatrics Corp. has higher upside potential than STAAR Surgical Co., analysts believe OrthoPediatrics Corp. is more attractive than STAAR Surgical Co..

OrthoPediatrics Corp. has a beta of 1.062, which suggesting that the stock is 6.186% more volatile than S&P 500. In comparison STAAR Surgical Co. has a beta of 1.008, suggesting its more volatile than the S&P 500 by 0.806%.

OrthoPediatrics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. STAAR Surgical Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrthoPediatrics Corp. pays -- of its earnings as a dividend. STAAR Surgical Co. pays out -- of its earnings as a dividend.

OrthoPediatrics Corp. quarterly revenues are $61.3M, which are smaller than STAAR Surgical Co. quarterly revenues of $94.7M. OrthoPediatrics Corp.'s net income of -$11.8M is lower than STAAR Surgical Co.'s net income of $8.9M. Notably, OrthoPediatrics Corp.'s price-to-earnings ratio is -- while STAAR Surgical Co.'s PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics Corp. is 1.87x versus 5.73x for STAAR Surgical Co.. Usually stocks with elevated PS ratios are considered overvalued.